Ben Huang, Astron MedTech - Minimally Invasive Surgical Device for Tendon Repair | LSI USA '24

Ben Huang  0:03  
Hello everyone, this is Ben from Astro med tech and then we're developing a minimally invasive device for soft tissue repair. But let me take you back to 7000 years ago, we all know Troy in a Trojan horse. rapid access Achilles in the movie and it was such an answering actors having been athletes and being a great warriors. However, his left ankle was being penetrated by Arrow was unfortunately killed during the battle. People notice that this is such an important issue, the naming Achilles tendons 7000 years later, sell a lot of patients from their 40 to 60 cells suffer from tenon ligament injuries. Even for athletes, John will quote that he could almost lie his foot because of infection. And why was that? It's because the invasive surgeries cut off three layers of the tendons and muscles and the fascia just to visualize the rupture site. Especially for Achilles tendon. This is how the surgery being performed nowadays, even in the market of the world. patients suffer from high complication rate, including infection and ruptures. That leads to high that leads to longer. readmissions. longer stay in hospital and readmissions, and patients suffer from long recovery time that it's been six to eight months of really painful journey. A lot of surgeon are asking for new solutions. And however there's not a lot of new options in the market. Therefore, we developed the Tammy suture system. That's a disposable kit that crank price of grasper adapter needle and suture holders that comes along with the suture and suture tape that helps us surgeons to perform minimally invasive surgeries. We can integrate it with ultrasound or arthroscopy to visualize the rupture site. And our products are compatible for suture anchors for you know, currently in the market. So from five feet 15 centimeters to only one centimeters, we create the smallest incision in the world. And what does that mean? It means that we can reduce a complication by 40% and larger reduces surgical time, meaning that there will be less complications in fashion readmissions and more happy surgeons. But for patients, I think that's really what matters is we can help them to recover within four months with full range of motions. And this technology we have published in three papers and there's more than 30 Call 330 surgeons have trained using our techniques in the cadaver settings and more than 33 clinical cases validated in IRB settings as well and walk you through some of the scientific evidence that we have done so far. So the first study that we did is attend kilise tendon minimally invasive repair with a two year follow up comparing with the invasive group. As we can see that we can significantly reduce the effect the complication rate from 28% to 4.3%. With the complications and for the patient function in the satisfactions, we can largely or increase the functions as well as their sense of satisfaction, satisfied vacations. And for some of the patient and invasive group, they were not able to have their range of motions fully recover after six months, and this is something that we'll be able to achieve. So with the ultrasound image that you can see this is a post op ultrasound image six months later using minimally invasive techniques, and honored to perform our surgeries which shows that there's a healthy tendons with no scar tissues. The next study, which is Hong Kong, formally, where there's a bony structure that will be removed by surgeons and we are attached to keys tendons, and we can the the outcome is fairly similar, we can reduce a complication rate and increase the functions for the patients. Compared to our competitor, we create the smallest incision in the world and the shortest recovery time. But I think most importantly is we protect the Cerner from brain damage. And that's something that our competitors are not able to achieve. Our global market is huge. We're currently focused on foot and ankle market, we're targeting a key tenant and hold on to for many, we're looking to even bigger market this format and market where we'll be able to perform rotator cuff cross app and atfl. And doors are a big market and we have validated in some of our clinical study that we'll be able to achieve with a set of techniques. The current market leader are taking around 25% of the market. And we're fairly confident that we'll be catch up on that within just three to four years. Our company was founded three years ago. And we have a solid animal study. And with that we file the patent we file three to four patents. And it's now been issued. So we have fully covered our systems as well as the whole method. Two years ago, we partnered with UC Berkeley and we get in to a lot of killings ASE and a hospital, such as Stanford or UCSF to let the surgeon test our device, increase the visibility, and based on that, we have found more patents to protect the whole systems. We want this global Select USA championship on the pitch competitions against three company, a global company and won the championship. And with that, we close our seed round with some of the investors during that events and some of the investor in internationally. And they'll help us to appreciate through manufacturing's and a lot of tests that were probably mentioned that were three to four months away from FDA approval. And after the launch of the product, we will be gathering more real world evidence and expanding our distributorship and having discussion with the strategics. Our team comprised of talented engineer and experienced surgeons, Dr. Juan is the president of Foot and Ankle society, and another Dr. Huang. So he's our major contributors. He's now the former dean of the hospitals. And Dr. Mark shoes. Oh, he's a sport man associate surgeon helping us to expand our indication to the upper extremities. So we're currently raising five millions together real world evidence and is, especially in states and scaling our distributors globally. We're asking from ad tech. We're raising five millions with our Series A and we're looking for distributor and r&d partnership. Thank you so much.